GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

Biosion .GlaxoSmithKline most significant contributions to the treatment of severe asthma has been the development and commercialization of a biologic medication called Nucala (mepolizumab).

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available ...

We are proud to have reached this meaningful milestone and are excited to transition our RespiRx™ Nicotine Inhaler into the real-world setting. Overall, we believe that today's news represents ...

UK pharma major GSK today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

Omalizumab (Xolair; Genentech, Novartis), dupilumab (Dupixent; Regeneron, Sanofi) and mepolizumab (Nucala, GSK) have varying effectiveness among patients with asthma and obesity, Mustafa said.

GSK’s Nucala was approved in the US for severe asthma with an eosinophilic phenotype treatment. Credit: MAXSHOT.PL / Shutterstock. The China National Medical Products Administration (NMPA) has ...

Jacob Bell GSK could soon answer Pfizer in the two pharmaceutical companies’ ongoing market battle to develop better meningitis vaccines. By Feb. 14, the FDA will decide whether to approve a shot ...

Bringing together over 8,000 industry leaders, emerging innovators and influential investors, the J.P. Morgan (JPM) Healthcare Conference is the most significant catalyst event for the healthcare ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy ...